🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🎉 Congratulations on receiving the #IJGC Top Reviewer Award! Thank you for setting the standard of excellence! 👏🤩 #TopReviewerAward #IGCS2024 Pedro T Ramirez Arthur_HC_Hsu Aarthi S Jayraj Andreina Fernandes IGCS ESGO European Network of Young Gynae Oncologists OncoAlert IJGC Fellows SoMe4GynOnc

The 15th ENGOT GCA workshop in Stresa 🇮🇹 Feeling so grateful for this great experience and the chance to learn from KOLs and meet amazing young colleagues! ESGO ENGAGe.ESGO European Network of Young Gynae Oncologists

#CervicalCancer: a new era Depending on stage, histology, and patient factors, the standard management of #cervicalcancer is a combination of treatment approaches 👀 bit.ly/41tWLao Pedro T Ramirez Arthur_HC_Hsu Aarthi S Jayraj Andreina Fernandes IGCS ESGO

If you missed this, it is NOW FREE! You can download it! All you need to know about cervical cancer with latest updates. Such an amazing teamwork! 💯🔝 IJGC IJGC Fellows ESGO European Network of Young Gynae Oncologists OncoAlert Pedro T Ramirez Arthur_HC_Hsu

Is IO in OC really a closed case? 🤔 Beyond DUO-O showing improved PFS with Bev-durv-ola vs Bev in tBRCAwt, two recent announcements: 1⃣ FIRST: Improved PFS with Bev-Dostar-Nirap vs Bev-Nirap. 2⃣ KEYLINK-001: Improved PFS with Bev-Pembro-Ola vs Bev in tBRCAwt. Stay tuned!

✨ 2024: A Breakthrough Year in Gynecologic Oncology! ✨ With 6 new FDA-approved drugs/indications, we're entering a brighter future for patients battling gynecological malignancies. Hope is stronger than ever! 💪

Check out this insightful review 📚📢 Incorporating immune checkpoint inhibitors in epithelial ovarian cancer - Gynecologic Oncology gynecologiconcology-online.net/article/S0090-… Giorgio Bogani DrKatyMoore Ray-Coquard Isabelle Jean Emmanuel Kurtz SGO

👌🏻👌🏻 Luigi De Vitis Gabriella Schivardi Francesco Multinu rosanu marina Ilaria Betella Giuseppe Caruso vanna zanagnolo Giovanni Aletti IEO IJGC

Incorporating immune checkpoint inhibitors in epithelial ovarian cancer SGO IGCS ESGO OncoAlert sciencedirect.com/science/articl…

📣 Just out our last paper on platinum rechallenge in pts with PROC in @GynOncJnls ⚠️ Platinum-free interval is not adequate to capture platinum resistance 🚨 We need a biomarker driven approach Thanks to all the coauthors! IEO Università degli Studi di Milano gynecologiconcology-online.net/article/S0090-…

Rechallenge with platinum-based chemotherapy 💉 in patients with platinum-resistant ovarian carcinoma 📈 SGO IGCS ESGO ASCO OncoAlert sciencedirect.com/science/articl…

#InLovingMemory 🖤 It is with profound sadness, we mourn the loss of a remarkable leader in gynecologic oncology, Professor Giovanni Scambia, whose unwavering dedication, exceptional surgical expertise, and deep commitment to mentorship have left an indelible mark in our field.

Amazing experience! Inspiring lectures on critical thinking and clinical research skills. Thanks ASCO AIOM Massimo Di Maio Bishal Gyawali, MD, PhD, FASCO Dario Trapani G Curigliano MD PhD Ian Tannock

Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial - The Lancet Oncology thelancet.com/journals/lanon…

🧬Not just molecular classification! 📢 Integrating molecular data with traditional risk factors is 🔑 to optimize #EndometrialCancer treatment strategies! Gabriella Schivardi IJGC The role of molecular classification in endometrial cancer: a focus on... sciencedirect.com/science/articl…

🙌ROSELLA ! Overall survival benefit (👍PFS benefit too) with the addition of relacorilant (glucocorticoid antagonist) to nab-paclitaxel in platinum resistant #ovariancancer 🎉🔥Another big win for our patients!!! #ASCO25 #gyncsm

#ASCO25 GSK FIRST presented today - I am proud of this trial as the US PI and the contribution of our sites and grace of our patients in participating. But- statistical significance did not translate to clinical relevance so we must say - no role for CPI in FL EOC.

📢 Exciting news for #ovariancancer patients! Another big achievement in a very challenging setting! Practice-changing results from the ROSELLA trial: relacorilant (a potent SGRM) plus nab-paclitaxel may become a new standard for PRROC. The Lancet sciencedirect.com/science/articl…

Lo studio Ascent-04/Keynote-D19, presentato ad ASCO 2025, mostra che sacituzumab govitecan e pembrolizumab migliorano il controllo e rallentano la progressione del tumore al seno triplo negativo.👉🏼Ce ne parla il Prof. G Curigliano MD PhD su Repubblica shorturl.at/RHVxW

Incredibly excited to share our work on LVM endometrial cancer patients! Giuseppe Caruso Francesco Multinu Luigi De Vitis Mayo Clinic IEO IJGC IJGC Fellows Glauco Baiocchi